Business
Odyssey Group International Provides Fiscal Year End July 31, 2020 Update
Odyssey Group International Provides Fiscal Year End July 31, 2020 Update.
About this update from Odyssey Health Inc.
[{"type":"text","content":"Company Continues to Advance Product Development ProgramsIRVINE, CA / ACCESSWIRE / December 7, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to provide the following update for its fiscal year ended July 31, 2020.Key Highlights from the Fiscal Year End July 31, 2020:Advanced product development of the Save a Life® choking rescue device with Tanaka Kapec Design GroupInitiated development of a mobile CardioMap® device that can be used in home or in point of care settingsAppointed Mike Contarino, an experienced medical device expert, to Lead Product Development ProgramsSigned Agreement with Majic LLC to Assist with Development of CardioMap® and Save a Life choking rescue device to insure highest-level quality in high volume manufacturing.Odyssey Chairman and Chief Executive Officer Michael Redmond, commented, "Odyssey was formed as a publicly held holding company with an emphasis on the development and acquisition of medical products and health related technologies. We are focused on building and acquiring technologies that have a technological advantage and a substantial market opportunity within significant target markets across the globe. We made great strides over the past twelve months in setting us up for success."Redmond, continued, "We now have a strong financial partner in place with Lincoln Park Capital. Our plan is to deploy capital to advance the development of our three different life saving technologies; the CardioMap® heart monitoring and screening device, the Save A Life® choking rescue device and a unique neurosteroid drug compound intended to treat rare brain disorders. We have our sights on readying these technologies and products for submission to the U.S. Food and Drug Administration (the "FDA")."Redmond, concluded, "Once the FDA clears us to market the CardioMap® and Save a Life® products, we intend to enter into agreements with qualified distributors throughout the United States and internationally, including: Europe, South America, Africa, India and China. Our objective is to grow revenue through marketing and sales of each of our medical devices, CardioMap® and Sav...